The Functional Diffusion Map: An Imaging Biomarker for the Early Prediction of Cancer Treatment Outcome  by Moffat, Bradford A. et al.
The Functional Diffusion Map: An Imaging Biomarker for the
Early Prediction of Cancer Treatment Outcome1
Bradford A. Moffat*, Thomas L. Chenevert*,2, Charles R. Meyer*, Paul E. Mckeever y, Daniel E. Hall*,
Benjamin A. Hoff*, Timothy D. Johnson z, Alnawaz Rehemtulla§,2 and Brian D. Ross*,2
Center for Molecular Imaging, Departments of *Radiology, yPathology, zBiostatistics, and §Radiation Oncology,
University of Michigan School of Medicine, Ann Arbor, MI, USA
Abstract
Functional diffusion map (fDM) has been recently re-
ported as an early and quantitative biomarker of clinical
brain tumor treatment outcome. ThisMRI approach spa-
tially maps and quantifies treatment-induced changes
in tumor water diffusion values resulting from altera-
tions in cell density/cell membrane function and micro-
environment. This current study was designed to
evaluate the capability of fDM for preclinical evaluation
of dose escalation studies and to determine if these
changes were correlated with outcome measures (cell
kill and overall survival). Serial T2-weighted and diffu-
sion MRI were carried out on rodents with orthotopi-
cally implanted 9L brain tumors receiving three doses
of 1,3-bis(2-chloroethyl)-1-nitrosourea (6.65, 13.3, and
26.6 mg/kg, i.p.). All images were coregistered to base-
line T2-weighted images for fDM analysis. Analysis of
tumor fDM data on day 4 posttreatment detected dose-
dependent changes in tumor diffusion values, which
were also found to be spatially dependent. Histologic
analysis of treated tumors confirmed spatial changes in
cellularity as observed by fDM. Early changes in tumor
diffusion valueswere found tobehighly correlativewith
drugdoseand independentbiologicoutcomemeasures
(cell kill and survival). Therefore, the fDM imaging
biomarker for early prediction of treatment efficacy can
be used in the drug development process.
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Introduction
The large number of watermolecules containedwithin tumor
tissues provides an important opportunity to quantify their
respective random trajectories (i.e., diffusion or Brownian
motion) for use as a noninvasive microscopic probe to as-
sess changes in tumor cell membrane integrity following
treatment intervention. This can be accomplished based
on the use of diffusion magnetic resonance imaging (MRI)
pulse sequences, which allows for three-dimensional tumor
images where the MR signal is dependent on the mobility of
water molecules within the tissue of interest [1]. Water can
reside within an intracellular compartment, where it is in a more
restricted environment relative to the extracellular compart-
ment; thus, intracellular water has lower apparent watermobility
(diffusion value). Changes in the ratio of the extracellular to
intracellular compartmental volumes (Ve/Vi) will significantly
affect the overall mobility of water within that measured tis-
sue region on the diffusionMR image. Treatment of a tumor with
an effective cytotoxic agent will result in an increase in the value
of the Ve/Vi ratio due to loss of cell membrane integrity and
subsequent loss in overall cellular density. Relative tissue
contrast on diffusion tumor maps is directly related to diffusion
values for each voxel in the image; therefore, the overall net
effect of a successful treatment would be an increase in the
fractional volume of the interstitial space, resulting in an in-
crease in water diffusion.
The application of diffusion MRI for the detection of early
tumor treatment response was first reported using a rodent gli-
oma model [2]. Subsequent publications have verified and ex-
panded this initial report using several different tumor models
and therapeutic agents [3–27]. Taken together, these studies
have shown that diffusion MRI is a sensitive biomarker that
is capable of detecting early cellular changes in treated tumors,
which precede macroscopic volumetric response. In addition, it
was also reported that diffusion MRI is a sensitive technique
that allows for the identification of spatially distinct regional
responses to therapy within tumor tissues [13,14,16–18,20].
Until recently, animal studies compared the mean apparent
diffusion coefficient (ADC) value from the entire tumor mass
posttherapy to the baseline (pretreatment) mean ADC value.
However, the response of ADC to cytotoxic therapy in the
clinical setting was found to be more complex due to heteroge-
neity observed within human tumors [11]. During the treatment
of patients with malignant brain tumors, it was shown that
diffusion changes could both increase (loss of intracellular
Abbreviations: MRI, magnetic resonance imaging; T2, MRI transverse relaxation time; ADC,
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space) and decrease (increase in intracellular space) over
time within the same tumor volume, especially for treatments
with modest efficacy [11,28]. This complicated response
scenario rendered the use of the mean change in overall
tumor ADC values less sensitive due to opposite and com-
peting effects. This observation required the development of
a new approach that could provide for the separation and
quantification of these competing changes. The idea was that
the Ve/Vi ratio could either increase or decrease during tumor
treatment; thus, both of these events required identification
within the diffusion image. To this end, functional diffusion
map (fDM) was developed as a statistical approach for
segmenting tumors based on a defined threshold of ADC
change following therapy [28].
Results from patients with primary malignant brain tumors
were analyzed using the fDM approach, which revealed that
the volume of fDM response had a strong correlation with
the overall clinical response based on the World Health Or-
ganization response criteria [28]. A more recent study [29],
wherein patients with grade III/IV gliomas were analyzed
using fDM, revealed that fDM could be used to stratify pa-
tients as responsive or nonresponsive to therapy in as early
as 3 weeks into a 6-week to a 7-week fractionated therapy
schedule. In this study, patients identified by fDM as non-
responsive had significantly poorer survival and time-to-
progression than patients identified as responsive [29]. Thus,
fDM has emerged as a predictive biomarker for the early
stratification of tumor response before therapy completion.
The purpose of this current study was to evaluate fDM as
an early, sensitive, and predictive tumor imaging biomarker in
the preclinical setting using a rodent gliomamodel. This study
is vitally important as it provides an opportunity to further as-
sess the fDM approach using a well-controlled experimental
tumor model.
The sensitivity of fDM was assessed by quantifying dif-
fusion changes in rat 9L tumors treated with different doses
of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)—a cytotoxic
drug often used clinically for the treatment of malignant gli-
omas. Three-dimensional fDM maps were computed from
MRI data obtained from individual animals pretherapy and
posttherapy. Analysis of tumor fDM data as early as 4 days
posttreatment was found to detect dose-dependent changes
in ADC maps. In addition, these changes were also found to
be spatially dependent and were found to correlate with his-
tologic changes in tumor cell density. These early treatment–
induced changes in tumor diffusion properties were also
found to be highly correlated with drug dose and animal
survival, suggesting that fDM is a valid early predictive bio-
marker for treatment efficacy. The fDM biomarker has poten-
tially broad applications in preclinical drug development and
in the individualization of cancer patient management.
Materials and Methods
Intracranial Tumor Implantation
All animal works were carried out in the animal facility of
the University of Michigan (Ann Arbor, MI) in accordance with
federal, local, and institutional guidelines. Intracerebral brain
tumors were implanted in male Fischer 344 rats (Charles
River Breeding Laboratories, Wilmington, MA) weighing
between 125 and 150 g. Animals were anesthesized by
intraperitoneal administration of a ketamine (87 mg/kg)/
xylazine (13 mg/kg) mixture. A small skin incision was made
over the right hemisphere, and a 1-mm-diameter burr hole
was drilled through the skull. A sterile suspension of 1  105
9L cells in 5 ml of serum-free medium was introduced through
a 27-gauge needle inserted to a depth of 3 mm. Rats were
allowed to recover after filling the burr hole with bone wax
and suturing the skin closed.
Chemotherapy
Thirty-three animals with 9L tumors were entered into the
study. When in vivo tumor volumes had reached 20 to 60 ml,
animals were divided into four groups. Group 1 received
0.1 ml of drug vehicle (10% ethanol) and was used as a con-
trol group (n = 7). Groups 2 to 4 received 6.65 mg/kg BCNU
(n = 7), 13.3 mg/kg BCNU (n = 11), and 26.6 mg/kg BCNU
(n = 8), respectively, diluted in 10% ethanol. All treatments
were administered by a single intraperitoneal injection on
day 0. T2-weighted (T2, MRI transverse relaxation time) and
diffusion MRI were performed every other day posttherapy
tomeasure volumetric and cell density changes, respectively.
Animal survival data were also obtained for all groups.
Diffusion MRI
Maps of tumor ADC values were acquired every other
day up to 14 days posttherapy using a previously described
method [11]. Briefly, a trace diffusion–weighted multislice
spin echo sequence (with motion compensation and naviga-
tor echo) was used to acquire 13 slices with two different
diffusion weightings [b1 = 100 sec/mm
2; b2 = 1248 sec/mm
2;
image slice thickness = 1 mm; image matrix = 128  128
(0–256); field of view = 30  30 mm; echo time = 60 milli-
seconds]. During all MRI procedures, the animals were anes-
thesized with 1.5% isoflurane, and body temperature was
maintained at 37jC using a heated water-recirculating pad.
The images acquired with b1 were essentially T2-weighted
images, and these were used to segment the tumor from
the normal brain for volumetric analysis using an ‘‘in-house’’
region drawing tool developed in MATLAB (Natick, MA).
Image Registration and fDM
An important part of fDM analysis is the registration of
parametric ADCmaps acquired posttherapy to baseline ADC
maps acquired before treatment. Image registration was
performed using an automated linear affine coregistration
algorithm (MIAMI Fuse; University of Michigan, Ann Arbor,
MI) to maximize mutual information between the two tempo-
rally distinct three-dimensional data sets [30]. Following
registration and tumor segmentation of voxels within the
tumor both at baseline and on day 4, fDM statistics were
calculated. Firstly, ADC values of voxels posttherapy were
plotted as a function of baseline ADC values. These tumor
voxels were then further segmented into three regions based
on an upper threshold and a lower threshold of ADC change.
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That is, tumor voxels that had increased ADC above the
upper threshold were region 1 (VR, red voxels), voxels that
had decreased below the lower threshold were region 2 (VB,
blue voxels), and all other voxels were region 3 (VG, green
voxels). A comparison between treatment groups and the
measurement of fDM dose dependence was accomplished
to optimize the sensitivity of the thresholds used (±0.4 
109 m2/sec). Normalized volumes were then calculated for
each animal, and group statistics were calculated.
Histopathology
In a separate study consisting of eight animals, two ani-
mals per treatment group were imaged pretreatment and
again at 6 to 7 days posttherapy. Following the second im-
aging session, animals were euthanized, and the brains were
fixed in 10% paraformaldehyde. After 48 hours, fixed tissues
were transferred to 70% ethanol and embedded in paraffin.
Formalin-fixed paraffin-embedded specimens were serially
sectioned and slide-mounted. Sections were stained with
hematoxylin and eosin (H&E) and compared to fDMs. This
was accomplished to identify underlying histologic changes
associated with observed regional alterations in fDMs.
Tumor Cell Kill Calculations and Statistical Analysis
The quantification of tumor cell kill from serially volumetric
imaging data for each animal was accomplished as pre-
viously described [31]. In brief, log(cell kill) = log10[Vpre/Vpost],
where V represents the tumor volume fromMRI. Linear least
squares analysis was used to measure the statistical signifi-
cance of trends in the BCNU dose dependence of fDM vol-
ume, animal survival, and log cell kill, and in the correlation of
fDM response with survival and cell kill. When two groups
were compared, a one-tailed Student’s t test was used.
Both linear least squares and Student’s t test were performed
using Microsoft Excel (Microsoft, Redmond, WA). To com-
pare the median survival of all four animal groups, a log rank
test was performed using Prism (GraphPad Software, Inc.,
San Diego, CA).
Results
Objective assignment of threshold-defining fDM regions is
required to provide optimal sensitivity for the detection of
therapy-induced changes. In this study, the normalized tumor
volume of region 1 (VR) was plotted (Figure 1a) as a function
of decreasing upper threshold for the four groups of ani-
mals investigated. Analysis of these data revealed that upper
thresholds of 0.2  109, 0.3  109, and 0.4  109 m2/sec
were all able to statistically differentiate between the three
treatment groups, and between the treatment groups and
the control group. At these thresholds, based on a one-tailed
t test,VRwas statistically different (P < .05) for all groups, with
VR being greater for the 26.6-mg/kg, 13.3-mg/kg, 6.65-mg/
kg, and control groups. In contrast, the same plot for the
lower threshold (Figure 1b) revealed that there was no sta-
tistical difference (P > .05) between the normalized volume of
region 2 (VB) for the control and the 6.65-mg/kg groups,
the 6.65- and the 13.3-mg/kg groups, or the 13.3- and the
26.6-mg/kg groups. However, the higher VB values of control
animals were found to be statistically significant (P < .05)
compared to the 13.3- and 26.6-mg/kg animals for thresholds
of 0.1  109 and 0.2  109 m2/sec. To minimize the VR
and VB volumes of the control group while maintaining sen-
sitivity to treatment-induced changes, a threshold of ±0.4 
109 m2/sec was used to identify/segment the three fDM
regions for all fDM images, scatter plots, and subsequent
statistical comparisons with outcome efficacy measures.
Functional diffusion mapping is a spatial mapping tech-
nique that segments diffusion MRI voxels within a tumor into
three distinct regions of diffusion change. Region 1 consists
of voxels wherein the change in ADC values from baseline to
posttherapy was greater than an upper threshold. These
regions are shown as red pixels on fDM images (Figure 2,
a, c, e, and g) and as red data points on fDM scatter plots
(Figure 2, b, d, f, and h). Region 2 represents voxels in which
the ADC change was less than a lower threshold and is
shown as blue pixels on fDM images and as blue data points
on scatter plots (Figure 2). Region 3 comprises voxels for
which ADC change was within the two thresholds and is
shown as green pixels and data points in Figure 2. These
examples of fDM images and scatter plots were taken from
a representative animal from each of the groups on day 4
posttreatment. The control tumor example (Figure 2, a and b)
Figure 1. fDM region volumes as a function of fDM threshold for the different
treatment groups. (a) The change in VR as a function of the upper threshold of
ADC change (m2/sec). (b) The change in VB as a function of the lower
threshold of ADC change (m2/sec). The bars represent the mean VR and VB
for each group at a given threshold, and the error bars represent the standard
error of the mean.
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Figure 2. Representative fDM maps and fDM scatter plots for each treatment group. The animals were treated with: (a and b) 0 mg/kg (control); (c and d) 6.65 mg/
kg BCNU; (e and f) 13.3 mg/kg BCNU; (g and h) 26.6 mg/kg BCNU. Images of fDMs (a, c, e, and g) reveal red voxels, which are regions with significant increases in
ADC, and blue voxels, which are regions within the tumor with significantly decreased ADC values. The green voxels are tumor regions wherein the ADC values did
not change (over the defined threshold level of ±0.4  109 m2/sec) over 4 days following treatment. Scatter plots corresponding to the fDM are voxel ADC values
posttreatment ( y-axis) as a function of the baseline (time 0) ADC value (x-axis).
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demonstrates how these tumors contained mostly region 3
voxels over this time frame, with the detected changes of VR
and VB representing only 2.9% and 5.7% of the total tumor
volume, respectively. However, the 6.65-mg/kg tumor shown
in Figure 2, c and d, contained responding voxels of VR =
7.7% and VB = 2.6%, respectively. The mean VR (10.6 ±
2.8%) and the mean ADC change (10.7 ± 2.2) for this group
were statistically significantly higher (P < .05) than those
for the control animals (VR = 3.9 ± 1.7; DADC = 0.8 ±
2.7%). For animals treated with 13.3 mg/kg BCNU, as shown
on the fDM image (Figure 2e) and scatter plots (Figure 2f ),
the responding region VR (30%) was greater than for both
the control and the 6.65-mg/kg–treated animals. The mean
VR (28.7 ± 8.0) and DADC (22.9 ± 5.3%) were both statisti-
cally greater (P < .05) than the values for the 6.65-mg/kg–
treated group. In the case of the 26.6-mg/kg BCNU–treated
group (Figure 2, g and h), most of the voxels contained within
the tumor mass had increased diffusion values above the
threshold (VR = 90.6%), with only 0.3% VB voxels. The group
mean VR (62.0 ± 9.0%) and the mean ADC change (49.0 ±
9.7%) were both statistically greater (P < .05) than those for
the 13.3-mg/kg–treated group.
Traditional measures of brain tumor treatment efficacy
were also evaluated in this study. Figure 3a shows a survi-
val plot for all groups of animals, revealing that there was a
dose-dependent increase in animal survival relative to the
control group. Using a log rank test, all groups had a statis-
tically significant difference in median survival posttherapy
(P< .05). In addition, normalized tumor volumeat 4 days post-
treatment displayed a decreasing trend with increasing
dose of BCNU (Figure 3b). Although the groups were not all
statistically different, the results of a linear least squares fit
showed that the slope was statistically significant (P < .05).
Lastly, log cell kill (Figure 3c) showed an increasing statistical
trend (P < .05) with dose, although the 6.65-mg/kg group
(0.25 ± 0.08) was not statistically greater (P > .05) than the
control group (0.09 ± 0.04). The log cell kill values of the
13.3-mg/kg (1.28 ± 0.18) and the 26.6-mg/kg (3.22 ± 0.51)
groups were both statistically different (P < .001) from each
other and from the control group.
The dose dependence of fDM based on the group means
(±SEM) forVR andVB valueswas also calculated. Figure 4 is a
plot of VR and VB as a function of drug dose (mg/kg). The re-
sulting ‘‘best-fit’’ gradient (2.30 ± 0.40 kg/mg) revealed that VR
was linearly correlated extremely well (P = 5.8  106) with
BCNU dose. In contrast, VB revealed very little correlation
(P = .87) with drug dose. Based on these results, it was ap-
parent that, for treatment of the 9L tumor with BCNU, the fDM
parameter that was most sensitive to drug-induced cellular
changes was VR. This parameter was then used for the sta-
tistical evaluation of fDM with additional outcome measures.
The ability of fDM to predict subsequent therapeutic out-
come, as quantified by overall animal survival, was eval-
uated. Figure 5 displays a plot of percent fDM change
(using the parameter VR) versus mean animal survival (days
posttreatment). The resulting gradient (1.55 ± 0.44, P = .002)
Figure 3. Dose dependence of traditional therapeutic efficacy measures. (a) Kaplan-Meier animal survival plots of animals treated with: (1) 0 mg/kg, (2) 6.65 mg/
kg, (3) 13.3 mg/kg, and (4) 26.6 mg/kg BCNU. The median survival for these groups was 7, 13, 23.5, and 35.5 days posttherapy, respectively. All groups were
significantly different, as determined by log rank test (P < .05). (b) Normalized tumor volume at the time fDM analysis was performed (4 days) posttreatment
with BCNU as a function of dose. The gradient of the least squares fit was 4.0 ± 1.3 (P = .004), and the intercept was 290 ± 20 (P = 1.4  1014). (c) Log cell kill
of the 9L tumor cells as a function of BCNU dose. The gradient of the least squares fit was 0.013 ± 0.02 (P = 3.7  109), and the intercept was 0.53 ± 0.21
(P = .02). The error bars represent the standard error of the mean for each group.
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showed that VR correlated very well with overall animal
survival. This finding strongly supports the use of fDM as a
biomarker that is capable of predicting early the overall out-
come (survival) following treatment administration.
The fDM approach provides interesting spatial information
not provided for in themean change in ADC approach.We in-
vestigated the underlying histologic basis for the observed
changes in the detected VR and VB fDM regions. Figure 6a
displays an fDM color overlay on its corresponding ana-
tomic image, which was acquired following treatment with
6.67 mg/kg BCNU. Histologic evaluation of the tumor section
prepared from this image region was undertaken. A magni-
fied view of the histologic section of the low-diffusion (VB)
region (high restriction of watermobility) is shown (Figure 6b).
This region was found to have very high cellular density.
In fact, this region contained 153 active mitoses as counted
from 10 high-power fields (original magnification, 40 objec-
tive lens). This is reflective of a region with a very high rate of
cellular proliferation. In distinct contrast, the region identified
by fDM as having very low restricted water diffusion (VR) was
identified by histology to have moderate cellular density.
This region was found to have a lower level of cellular pro-
liferation (96 mitoses in 10 high-power fields) than the VB re-
gion (Figure 6c).
Discussion
Biomarkers that are sensitive to treatment-induced changes
are actively being sought to confirm drug activity or to pre-
select those patients who are more likely to respond to
treatment. An imaging biomarker for this should be capable
of detecting relevant drug-induced changes within a tumor.
The successful identification and validation of an imaging
biomarker that could provide early prediction of treatment
outcome would potentially revolutionize cancer drug devel-
opment and the clinical management of oncology patients.
Furthering the urgency of this need is the fact that, after
20 years of research, the clinical benefits of drugs designed
to exploit cancer gene-based targets display a significant im-
pact. However, targeted therapies cannot be optimally de-
veloped using approaches designed for more traditional
cytotoxic chemotherapies, as the maximum tolerated dose
may not indicate optimal dose; dose-limiting toxicity may
not be proliferation-linked, and myelosuppression side ef-
fects cannot be used as surrogate markers of cytotoxicity
because many of these effects do not deplete blood cells.
These facts highlight the urgent need to find and develop
pharmacodynamic and prognostic markers to establish opti-
mal dosing and to confirm that new agents have their desired
biochemical effects. An imaging biomarker revealing that cell
death occurs in a solid tumor, for example, can demonstrate
that an experimental agent kills tumor cells without the long
delay traditionally required to reach a clinical endpoint.
Nonimaging-based biomarkers are used by two methods.
The first approach uses prognostic markers that are pref-
erably identified through DNA microarrays that match new
classes of drugs with the molecular profile of an individual
tumor. If a drug is targeted specifically against cells that
have a particular mutation, translocation, or gene overex-
pression, then testing tumor tissues to determine whether
Figure 4. Dose dependence of detectable changes in fDM parameters VR
and VB. (a) Mean normalized volume VR (%) as a function of BCNU dose. The
gradient of the least squares fit was 2.30 ± 0.40 (P = 5.8  106), and
the intercept was 1.1 ± 6.2 (P = .87). (b) Mean normalized volume VB as
a function of BCNU dose. The gradient of the least squares fit was 0.10 ±
0.07 (P = .17), and the intercept was 4.5 ± 1.1 (P = .005). The error bars rep-
resent the standard error of the mean for each group.
Figure 5. Correlation of fDM VR changes with animal survival and cell kill. (a) VR volumes calculated 4 days post-BCNU therapy are plotted as a function of the
median survival for each of the treatment groups. The error bars represent the standard error of the mean for each group. The gradient of the least squares fit was
1.55 ± 0.44 (P = .002), and the intercept was 6.2 ± 9.8 (P = .53). (b) Change in percent fDM versus log cell kill measured using MRI tumor volume measurements
over time.
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such molecular profile is present in a tumor may help clini-
cians avoid prescribing ineffective treatments. The second
method uses pharmacodynamicmarkers that are designed to
provide information as to whether a drug is manifesting its
intended biochemical effect, and, if so, to what extent. In the
long term, these pharmacodynamic effects could be used as
surrogate markers for clinical response. However, these
nonimaging-based approaches use tissue specimens and,
as such, do not take into account the tremendous heteroge-
neity exhibited by tumors. Moreover, different agents will
target different molecular sites within the tumor, thus poten-
tially requiring a plethora of biomarkers, with each requiring
independent validation.
A noninvasive imaging approach is preferred because
imaging is sensitive and minimally invasive, and can provide
multidimensional multislice images with exquisite resolution
at multiple time points. Initial diffusion MRI Clinical Studies
have revealed that treatment-induced changes could be
observed within tumors [11,33–37]. The functional diffu-
sion mapping approach evaluated in this study is an in vivo,
translatable, quantifiable, noninvasive multislice imaging
biomarker, which was shown to be very sensitive to early
therapy-induced alterations in tumor cell membrane integrity
[28,29]. Thus, the use of changes in tumor water diffusion as
biomarker for microscopic changes associated with success-
ful treatment intervention provides an important opportunity
for assessing a broad range of drugs.
An important aspect of translating any biomarker is that it
undergoes adequate validation and should correlate with
biologically relevant endpoints. In this current study, the dose
response of fDM in brain tumors was compared to traditional
endpoints, including tumor growth, cell kill, histopathology,
and animal survival. Compared to tumor volume and cell kill
measures of outcomes that had significant trends but no
statistical differences between vehicle control and 6.65-mg/
kg–treated animals, fDM was shown to be a superior mea-
surement of treatment efficacy (Figure 3, b and c).
An excellent correlation of fDM response with increasing
BCNU dose (Figure 4a) and the significant differences in
fDM-measured responses between all dosage groups were
shown. The ‘‘gold standard’’ of efficacy measures in ortho-
topic experimental tumor models has traditionally been ani-
mal survival. In this current study, we found fDM response
quantified at 4 days posttreatment to be highly correlated
with animal survival and cell kill (Figure 5, a and b). Perhaps
one of the most interesting findings was that the low dose
(6.65mg/kg) was barely effective as it only increased survival
by an average of 5.5 days; however, fDM was, in fact, sen-
sitive enough to detect a significant difference from the con-
trol group of animals and from higher treatment doses. Thus,
the excellent correlation of fDM change with animal survival
outcome provides compelling evidence that this is a valid bio-
marker for the early detection and prediction of biologically
relevant outcome measures (survival and cell kill). Further-
more, fDM was recently shown to be able to stratify thera-
peutically responsive glioma patients from nonresponsive
patients in as early as 3 weeks into a 6-week to a 7-week
treatment schedule [29]. These data revealed that fDM could
identify early patients who are prone to having significantly
poorer survival and time-to-progression from those patients
whowould have amuchmore responsive outcome [29]. These
data, along with clinical results, reveal that fDM can be ef-
fectively used as a predictive biomarker for the early strati-
fication of tumor response before completion of therapy in
both preclinical and clinical oncology studies.
An important aspect of fDM is that it maintains spatial im-
aging information, thus providing it with an exciting advantage
over other possible biomarker approaches, such as geno-
mic and proteomic approaches. This is a particular advantage
given that treatment response can be extremely hetero-
geneous due to a variety of reasons, such as differential drug
delivery and spatially varying heterogeneity in tumor pheno-
type expression levels. The advantage of this is quite evi-
dent as revealed in this histologic assessment (Figure 6) of
Figure 6. Histologic evaluation of fDM VR and VB regions. (a) A representative fDM image of a 9L tumor showing a heterogeneous response to BCNU (6.65 mg/kg)
treatment. The fDM image revealed regions of high (blue) and low (red) restriction of diffusion. (b) H&E-stained slice from a region identified as an fDM (VB) region
of restricted diffusion. This region of high tumor diffusional restriction contained decreased amounts of extracellular space, as shown in the H&E image. In addition,
this region was found to contain 153 mitoses in 10 high-power fields (original magnification, 40 objective lens), reflecting a high rate of proliferation. (c) A region of
low restriction (VR) is shown to have a moderate level of cellular density, as shown in the H&E image. This region contained 96 mitoses in 10 high-power fields,
reflecting mitoses that are fewer than those in the previous region (VB).
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different fDM regions (VR and VB). These data revealed that
VR correlated with a region of significant treatment-induced
cell death. However, foci of tumor regions undergoing rapid
cellular proliferation were also detected by VB as regions
of greatly reduced water mobility, confirmed by histology
as focal regions of high cell density along with high mitotic
index. These regions of increased proliferation were not ob-
served with higher doses of BCNU treatment (Figure 2, e–h).
In fact, the increased dose had an additional effect of increas-
ing the overall percentage of the VR region and of shifting
the distribution of green voxels to a higher level (on average),
as shown on scatter plots (Figure 2, f and h). This indicates
that a dynamic shift in the overall tumor cytoarchitecture to-
ward a loss of cell density/membrane integrity occurred fol-
lowing treatment.
In this study, it has been shown that fDM is a viable, quan-
tifiable, and early imaging biomarker of treatment response,
as it was shown to correlate with traditional biomarkers of
efficacy such as survival and cell kill. The advantages of fDM
include the following: 1) acquisition of this imaging data can
be accomplished rapidly (in seconds); and 2) it provides a
much more timely readout over traditional outcome mea-
sures. The ability to rapidly assess efficacy following treat-
ment initiation provides an important opportunity to more
rapidly evaluate drug dosages and combinations in pre-
clinical studies. Moreover, because fDM is a translatable
technique, inclusion of fDM in phase 1 and 2 clinical trials
would provide a sensitive means to detect treatment efficacy,
which is especially valuable in dose escalation protocols.
Furthermore, fDM provides the potential to truly individu-
alize patient treatment regimens through unbiased quantiza-
tion of early treatment response. This has tremendous clinical
significance as it could facilitate early identification of pa-
tients who are nonresponsive to a specific intervention and
thereby provide more time to try alternative therapies. Utili-
zation of fDM in this fashion would be an invaluable and
cost-effective approach for managing individual patients
undergoing anticancer treatment. Further impact could be
seen in improvements in patients’ quality of life and extension
of overall survival.
In conclusion, this study has validated fDM as an imag-
ing biomarker in a preclinical tumor model. Although this
approach should be further examined in additional tumor
models, we have shown clearly the power of using fDM as
a biomarker for the early detection of cancer treatment
response in the 9L model. The important properties of this
in vivo imaging biomarker include the following: its trans-
latability to the clinical setting [28,29]; its quantitative na-
ture, which is independent of the manufacturing of the MRI
instrument and of magnetic field strength; the close cor-
relation with primary biologic endpoints, including overall
histology, cell kill, and survival; and its ease of use and cost-
effectiveness. These results provide an important foundation
for using diffusion MRI to individualize the treatment of cancer
patients. Data presented in this study provide compelling
evidence for the need to rapidly advance the application of
diffusion MRI and fDM in the preclinical setting and in the
oncology clinic.
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